OncoMed Pharmaceuticals Inc Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014
Assets
Current assets:
Cash
Cash and cash equivalents
Short-term investments
Receivables - related parties
Receivables-related parties
Accounts receivable
Tax receivables
Accounts receivable and other receivables
Tax receivable
Prepaid and other current assets
Assets held for sale
Total current assets

Property and equipment, net
Other assets
Total assets
Liabilities and stockholders' deficit
Current liabilities:
Accounts payable
Income tax payable
Accrued liabilities
Accrued clinical liabilities
Current portion of deferred revenue
Current portion of deferred rent
Liability for shares issued with repurchase rights
Total current liabilities

Deferred revenue, less current portion
Deferred rent, less current potion
Noncurrent income tax payable
Liability for shares issued with repurchase rights, less current portion
Other liabilities
Total liabilities
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2018 and 2017; no shares issued and outstanding at December 31, 2018 and 2017
Common stock, $0.001 par value; 145,000,000 shares authorized at December 31, 2018 and 2017; 38,660,146 and 38,212,505 shares issued and outstanding at December 31, 2018 and 2017, respectively
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total stockholders’ equity (deficit)

Total liabilities and stockholders’ equity (deficit)

Comments